Curriculum Vitae

Marcus A. Mall Professor, Dr. med.
d.o.b. 05th of October 1968

University Education

2007	Habilitation, Pediatrics and Adolescent Medicine, University of Heidelberg
1997	Doctorate, Medicine (M.D.), University of Freiburg
1990 - 1997	Studies of Medicine University of Freiburg, Germany and University College London School of Medicine, London, UK

Scientific Career

Since 2021	Deputy Speaker of the CRC 1449 'Dynamic Hydrogels at Biointerfaces'
Since 2021	Coordinator of the Berlin site of the German Center for Child and Youth Health (DZKJ)
Since 2019	Coordinator of the Innovationsfonds project "conneCT CF" (GBA)
Since 2018	Full Professor (W3) and Director of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin
Since 2018	BIH Professor, Berlin Institute of Heath (BIH)
2012 - 2018	Director of the Department of Translational Pulmonology and Chairman of the Translational Lung Research Center Heidelberg (TLRC), Member of the German Centre for Lung Research (DZL)
Since 2012	Coordinator, Disease Area Cystic Fibrosis, German Center for Lung Research (DZL)
2011 - 2018	Founding Director and Member of the Executive Board, German Centre for Lung Research (DZL)
2009 - 2012	Heisenberg Professorship (W3) for Translational Pulmonology (DFG) and Head of the Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics, University of Heidelberg
2006 - 2018	Group leader at the Molecular Medicine Partnership Unit (MMPU) of the University of Heidelberg and the European Molecular Biology Laboratory (EMBL)
2006 - 2018	Faculty Member of the Hartmut Hoffmann-Berling International Graduate School of Molecular & Cellular Biology Heidelberg (HBIGS)
2005 - 2009	Group leader of EU-funded Independent Junior Research Group "Cystic Fibrosis / Chronic Airway Disease" (Marie Curie Excellence Team)
2004 - 2006	Fellow in Pediatric Pulmonology, Department of Pediatrics, University of Heidelberg
2003 - 2004	Assistant Professor, School of Medicine, UNC, Chapel Hill, NC, USA
2000 - 2003	Postdoc, CF/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill (UNC), Chapel Hill, NC, USA
1997 - 2000	Resident, University Children's Hospital, University of Freiburg

Awards and Honors (selected)

2020	Adalbert Czerny Prize, German Society of Pediatrics and Adolescent Medicine (DGKJ)
2020	Excellence Award for Research in Cystic Fibrosis, European Respiratory Society (ERS)
Since 2017	Fellow of ERS (FERS)
2009	Heisenberg-Professorship, German Research Foundation (DFG)
2009	Research Award, German Society of Pulmonology (DGP)
2005	Marie Curie Excellence Grant (EU 6. Framework Programme)
2005	Johannes Wenner Prize, German Society of Pediatric Pulmonology (GPP)
2000 - 2002	Research Fellowship, German Research Foundation (DFG)
1997	Adolf Windorfer Prize, German Cystic Fibrosis Association

Citation Record

Total citations: 11,191; *h-index: 55* (Web of Science 29th of July 2022)

Top-10 selected Publications

Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, Prais D, Pressler T, Ratjen F, Reix P, Robinson PD, Selvadurai H, Stehling F, Ahluwalia N, Arteaga-Solis E, Bruinsma BG, Jennings M, Moskowitz SM, Noel S, Tian S, Weinstock TG, Wu P, Wainwright CE, Davies JC; VX19-445-116 Study Group. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for *F508del* and a Minimal Function Mutation: A Phase 3B, Randomized, Placebo-Controlled Study. *Am J Respir Crit Care Med* 2022.

Graeber SY, Renz DM, Stahl M, Pallenberg ST, Sommerburg O, Naehrlich L, Berges J, Dohna M, Ringshausen FC, Doellinger F, Vitzthum C, Rohmel J, Allomba C, Hammerling S, Barth S, Ruckes-Nilges C, Wielputz MO, Hansen G, Vogel-Claussen J, Tummler B, **Mall MA***, Dittrich AM*. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med* 2022. (*equal contribution)

Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tummler B, **Mall MA**. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med* 2022;205:540-549.

Sutharsan S, McKone EF, Downey DG, Duckers J, MacGregor G, Tullis E, Van Braeckel E, Wainwright CE, Watson D, Ahluwalia N, Bruinsma BG, Harris C, Lam AP, Lou Y, Moskowitz SM, Tian S, Yuan J, Waltz D, **Mall MA**, group VXs. Efficacy and safety of elexacaftor plus tezacaftor plus ivacaftor versus tezacaftor plus ivacaftor in people with cystic fibrosis homozygous for F508del-CFTR: a 24-week, multicentre, randomised, double-blind, active-controlled, phase 3b trial. *Lancet Respir Med* 2022;10:267-277.

Loske J, Röhmel J, Lukassen S, Stricker S, Magalhães VG, Liebig J, Chua RL, Thürmann L, Messingschlager M, Seegebarth A, Timmermann B, Klages S, Ralser M, Sawitzki B, Sander LE, Corman VM, Conrad C, Laudi S, Binder M, Trump S, Eils R, **Mall MA***, Lehmann I*. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol*. 2022 Mar;40(3):319-324. (*equal contribution).

Barry PJ*, **Mall MA***, Álvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D; VX18-445-104 Study Group. Triple Therapy for Cystic Fibrosis *Phe508del*-Gating and -Residual Function Genotypes. *N Engl J Med*. 2021 Aug 26;385(9):815-825. (*equal contribution).

Hey J, Paulsen M, Toth R, Weichenhan D, Butz S, Schatterny J, Liebers R, Lutsik P, Plass C, **Mall MA**. Epigenetic reprogramming of airway macrophages promotes polarization and inflammation in muco-obstructive lung disease. *Nat Commun* 2021; 12:6520

Duerr J, Leitz DHW, Szczygiel M, Dvornikov D, Fraumann SG, Kreutz C, Zadora PK, Seyhan Agircan A, Konietzke P, Engelmann TA, Hegermann J, Mulugeta S, Kawabe H, Knudsen L, Ochs M, Rotin D, Muley T, Kreuter M, Herth FJF, Wielputz MO, Beers MF, Klingmuller U, **Mall MA**. Conditional deletion of Nedd4-2 in lung epithelial cells causes progressive pulmonary fibrosis in adult mice. *Nat Commun* 2020; 11:2012.

Middleton PG*, **Mall MA***, Dřevínek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with a single Phe508del allele. *N Engl J Med.* 2019;381:1809–1819. (*equal contribution)

Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. *Nat Med* 2004;10:487-493